Marts 2023: CAR-T-cell therapy is a novel and effective cancer treatment modality that has revolutionized the treatment of cancer, particularly blood cancers. This therapy achieves a therapeutic effect or cures disease by repairing or reconstructing genetic materials that have been damaged. Since Roseberg first isolated tumour-infiltrating lymphocytes (TILs) to treat melanoma in 1986, the development of modified T cell therapy has gained significant momentum. Since the FDA approved the first CAR-T terapija, Kymriah, in 2017, the CAR-T market has grown rapidly. According to Frost & Sullivan, the global CAR-T market size is projected to increase from USD 10 million in 2017 to USD 1.08 billion in 2020, and then to USD 9.05 billion in 2025, with a compound annual growth rate (CAGR) of 55% from 2019 to 2025, making it the fastest-growing segment of the global cell and gene therapies (CGT) market.
CAR-T therapy is one of CGT therapy’s subsegments. On the basis of the origin of T cells, CAR-T therapy can be divided into two categories. Autologous CAR-T-cell therapy, which employs the patient’s own immune cells, and allogeneic CAR-T-cell therapy, which employs T cells from donor blood or occasionally umbilical cord blood,. The majority of CAR-T therapies are autologous CAR T-šūnu terapija, which typically involve the steps outlined below:
Jūs varētu vēlēties lasīt: CAR T šūnu terapija Ķīnā
1) T šūnas tiek iegūtas no pacienta perifērajām asinīm;
2) Viral vectors such as AAV then modify T cells with CAR genes that are directed against a specific cell-surface protein on cancer cells;
3) The modified CAR-T cells population is expanded according to the patient’s weight;
4) The expanded CAR-T cells are then reinfused back into the patient. The entire manufacturing procedure lasts between one and three weeks and requires GMP compliance in an ultra-clean environment.
CAR-T therapy has reached a level of success that has never been seen before in treating B-cell cancers that are resistant to or refractory to chemotherapy, including R/R, B-ALL, NHL, and MM. The effectiveness of treating solid tumours is also currently under investigation. CD19-targeting and BCMA-targeting CAR-T therapies achieve the greatest clinical success among all CAR-T therapies. Four of the six CAR-T therapies approved by the FDA target CD19, while two target BCMA.
The most significant advantage over small and large molecule drugs is that patients can replace lifelong treatment of chronic disease with a limited number of doses, or even just one.
The United States pioneered the development of the CAR-T industry. However, by the middle of the 2010s, China had learned quickly and was catching up to the United States. Principally, the key drivers can be attributed to the Chinese government’s support for the development of a CGT ecosystem comprised of biotech companies, academics, healthcare providers, investors, and the government. Following the prioritization of biotechnology in the thirteenth five-year plan, the Chinese government emphasized its strategy to accelerate the innovation and development of biotech industries, including cell therapy. In addition, pertinent ministries have issued encouraging action regulations.
Pēc Valsts padomes atzinumu par zāļu un medicīnisko ierīču novērtēšanas, pārskatīšanas un apstiprināšanas sistēmas reformas publicēšanas 2015. gadā aktivizējās arī kapitāla tirgus. Ar salikto gada pieauguma tempu 45%, Ķīnas šūnu terapijas uzņēmumi no 2.4. līdz 2018. gadam piesaistīja finansējumu aptuveni USD 2021 miljardu apmērā.
Jūs varētu vēlēties lasīt: CAR T šūnu terapijas izmaksas Ķīnā
The number of CAR-T therapy trials in China surpassed those in the United States by 2018 as a result of this thriving ecosystem. As of June 2022, Chinese companies had conducted 342 clinical CAR-T trials. Malignancies in the B lineage were among the most prevalent manifestations. Two CAR-T products have commercial applications: Jācarta in June 2021 and Relma-cel in September 2021, among numerous drug candidates.
Saskaņā ar Frost & Sullivan datiem tiek prognozēts, ka vietējais CAR-T tirgus palielināsies no 0.2 miljardiem CNY 2021. gadā līdz 8 miljardiem CNY 2025. gadā un pēc tam līdz 28.9 miljardiem CNY 2030. gadā ar CAGR 45% no 2022. līdz 2030. gadam. fakts, ka Ķīnas CAR-T tirgus joprojām ir sākumstadijā, pastāv spēcīgs dzinējspēks.
Although the two approved CAR-T products are from Sino-US joint ventures Fosun Kite and JW Terapeutics, domestic players have made breakthroughs and caught up to global players in recent years. Legend Biotech, IASO Biotherapeutics, and CARsgen Therapeutics all obtained NDA approval for their BCMA CAR-T products, establishing them as the leaders in BCMA CAR-T therapy. CD19 CAR-T products are a focus for Juventas Therapeutics, Gracell Biotechnologies, Hrain Biotechnology, ImunoPharm, Shanghai Cell Therapy Group, and numerous domestic companies. Juventas Therapeutics is the leader in Chinese CD19 CAR-T terapija now that the NMPA has accepted its NDA for CNCT19. CARsgen Therapeutics is a global leader in solid tumours, and CT041 is the first CAR-T candidate for treating solid tumours to enter Phase II klīniskie pētījumi. Bioheng Biotech un BRL Biotech (ķīniešu: ) izveido jaunus alogēnus CAR-T tirgus.
Jūs varētu vēlēties lasīt: CAR T šūnu terapija multiplās mielomas ārstēšanai Ķīnā
